{"id":5939,"date":"2025-02-04T15:05:03","date_gmt":"2025-02-04T21:05:03","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5939"},"modified":"2025-07-13T15:11:27","modified_gmt":"2025-07-13T20:11:27","slug":"nanoscope-announces-presentations-at-medical-meetings","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2025\/02\/04\/nanoscope-announces-presentations-at-medical-meetings\/","title":{"rendered":"Nanoscope Therapeutics anuncia presentaciones en pr\u00f3ximas reuniones m\u00e9dicas"},"content":{"rendered":"
\n
\n
\n
\n
\n

<\/h1>\n<\/div>\n
\n
\n

DALLAS<\/span><\/span>,\u00a04 de febrero de 2025<\/span><\/span>\u00a0 \u2014 Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda dedicada a restaurar la visi\u00f3n en pacientes ciegos en situaciones reales mediante el desarrollo y la comercializaci\u00f3n de nuevas terapias gen\u00e9ticas para enfermedades degenerativas de la retina, anunci\u00f3 hoy presentaciones en dos pr\u00f3ximas reuniones m\u00e9dicas. Los detalles de las presentaciones son los siguientes:<\/p>\n

22.\u00aa Reuni\u00f3n Anual del Instituto Oftalmol\u00f3gico Bascom Palmer sobre Angiog\u00e9nesis, Exudaci\u00f3n y Degeneraci\u00f3n<\/b><\/a><\/p>\n

T\u00edtulo:<\/b>\u00a0Eficacia y seguridad longitudinales de la terapia optogen\u00e9tica MCO-010 para la restauraci\u00f3n de la visi\u00f3n en pacientes con p\u00e9rdida grave de la visi\u00f3n debido a retinitis pigmentosa: resultados de 126 semanas de un estudio de seguimiento a largo plazo (REMAIN)
T\u00edtulo de la sesi\u00f3n:\u00a0<\/b>Degeneraciones hereditarias de la retina
Fecha de la sesi\u00f3n:\u00a0<\/b>S\u00e1bado 8 de febrero de 2025
Tiempo de sesi\u00f3n:\u00a0<\/b>6:25 pm hora del este<\/span>
Presentador:\u00a0<\/b>Allen Ho, MD, FACS, FASRS, Director de Investigaci\u00f3n de Retina y Codirector del Servicio de Retina en Wills Eye Hospital, y Asesor M\u00e9dico Jefe de Nanoscope<\/p>\n

El Dr. Ho participar\u00e1 en una mesa redonda sobre distrofias retinianas hereditarias (DRH), para varias de las cuales Nanoscope est\u00e1 desarrollando tratamientos restauradores. En este contexto, el Dr. Ho presentar\u00e1 datos de 126 semanas del estudio de seguimiento a largo plazo REMAIN de Nanoscope, realizado en pacientes con retinosis pigmentaria avanzada tratados en el ensayo cl\u00ednico aleatorizado RESTORE.<\/p>\n

48.\u00aa reuni\u00f3n anual de la Sociedad de la M\u00e1cula<\/b><\/a><\/p>\n

T\u00edtulo:<\/b>\u00a0Eficacia y seguridad de la terapia optogen\u00e9tica MCO-010 para la restauraci\u00f3n de la visi\u00f3n en pacientes con p\u00e9rdida grave de la visi\u00f3n debido a retinosis pigmentaria: resultados principales de 126 semanas del estudio de seguimiento REMAIN (REMAIN)
T\u00edtulo de la sesi\u00f3n:\u00a0<\/b>Distrofia retiniana hereditaria I
Fecha de la sesi\u00f3n:\u00a0<\/b>Jueves 13 de febrero de 2025
Tiempo de sesi\u00f3n:<\/b>\u00a07:05 am ET<\/span>
Presentador:\u00a0<\/b>V\u00edctor Gonz\u00e1lez<\/span>, MD, Gulf Coast Eye Institute e investigador del ensayo REMAIN<\/p>\n

El Dr. Gonz\u00e1lez presentar\u00e1 y analizar\u00e1 los datos de eficacia y seguridad del seguimiento a largo plazo de la terapia optogen\u00e9tica MCO-010 de Nanoscope para la restauraci\u00f3n de la visi\u00f3n en pacientes con p\u00e9rdida grave de la visi\u00f3n debido a retinosis pigmentaria.<\/p>\n

Acerca de Nanoscope Therapeutics Inc.
<\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas que restauran la visi\u00f3n y que no dependen de los genes para los millones de pacientes que han perdido la visi\u00f3n a causa de enfermedades degenerativas de la retina, para las que actualmente no existe cura. Tras los resultados positivos de final de estudio del ensayo cl\u00ednico RESTORE de fase 2b, multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo para la RP (NCT04945772<\/a>), la compa\u00f1\u00eda anunci\u00f3 su plan de iniciar un\u00a0Presentaci\u00f3n de BLA para MCO-010 para tratar RP<\/a>\u00a0en el primer trimestre de 2025. La empresa ha completado el ensayo STARLIGHT de fase 2 de la terapia MCO-010 en pacientes con Stargardt (NCT05417126<\/a>) y planea iniciar una\u00a0Ensayo de registro de fase 3<\/a>\u00a0en el primer trimestre de 2025. MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para RP como para Stargardt. Los programas precl\u00ednicos incluyen un activo MCO-020 no viral administrado por l\u00e1ser listo para IND para GA, as\u00ed como un activo AAV para amaurosis cong\u00e9nita de Leber, en estudios que permiten IND.<\/p>\n

Contacto de inversores:<\/b>
Socios Argot
212-600-1902
PR@nanostherapeutics.com<\/a><\/p>\n

FUENTE Terap\u00e9utica del Nanoscopio<\/p>\n

\"\"<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

DALLAS,\u00a0Feb. 4, 2025\u00a0 \u2014 Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced presentations at two upcoming medical meetings. Details of the presentations are as follows: Bascom Palmer Eye Institute\u2019s 22nd Annual Angiogenesis, Exudation, and […]<\/p>\n","protected":false},"author":6,"featured_media":5941,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5939","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Announces Presentations at Upcoming Medical Meetings - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2025\/02\/04\/nanoscope-announces-presentations-at-medical-meetings\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Presentations at Upcoming Medical Meetings - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2025\/02\/04\/nanoscope-announces-presentations-at-medical-meetings\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-04T21:05:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-13T20:11:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/02\/NSCOPE_upoming_med_mtgs_feature.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/02\/NSCOPE_upoming_med_mtgs_feature.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/02\\\/04\\\/nanoscope-announces-presentations-at-medical-meetings\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/02\\\/04\\\/nanoscope-announces-presentations-at-medical-meetings\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Announces Presentations at Upcoming Medical Meetings\",\"datePublished\":\"2025-02-04T21:05:03+00:00\",\"dateModified\":\"2025-07-13T20:11:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/02\\\/04\\\/nanoscope-announces-presentations-at-medical-meetings\\\/\"},\"wordCount\":421,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/02\\\/04\\\/nanoscope-announces-presentations-at-medical-meetings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/NSCOPE_upoming_med_mtgs_feature.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/02\\\/04\\\/nanoscope-announces-presentations-at-medical-meetings\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/02\\\/04\\\/nanoscope-announces-presentations-at-medical-meetings\\\/\",\"name\":\"Nanoscope Therapeutics Announces Presentations at Upcoming Medical Meetings - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/02\\\/04\\\/nanoscope-announces-presentations-at-medical-meetings\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/02\\\/04\\\/nanoscope-announces-presentations-at-medical-meetings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/NSCOPE_upoming_med_mtgs_feature.jpg\",\"datePublished\":\"2025-02-04T21:05:03+00:00\",\"dateModified\":\"2025-07-13T20:11:27+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/02\\\/04\\\/nanoscope-announces-presentations-at-medical-meetings\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/02\\\/04\\\/nanoscope-announces-presentations-at-medical-meetings\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/02\\\/04\\\/nanoscope-announces-presentations-at-medical-meetings\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/NSCOPE_upoming_med_mtgs_feature.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/NSCOPE_upoming_med_mtgs_feature.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/02\\\/04\\\/nanoscope-announces-presentations-at-medical-meetings\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Presentations at Upcoming Medical Meetings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics anuncia presentaciones en pr\u00f3ximos congresos m\u00e9dicos - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2025\/02\/04\/nanoscope-announces-presentations-at-medical-meetings\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Announces Presentations at Upcoming Medical Meetings - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2025\/02\/04\/nanoscope-announces-presentations-at-medical-meetings\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-02-04T21:05:03+00:00","article_modified_time":"2025-07-13T20:11:27+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/02\/NSCOPE_upoming_med_mtgs_feature.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/02\/NSCOPE_upoming_med_mtgs_feature.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/02\/04\/nanoscope-announces-presentations-at-medical-meetings\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/02\/04\/nanoscope-announces-presentations-at-medical-meetings\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Announces Presentations at Upcoming Medical Meetings","datePublished":"2025-02-04T21:05:03+00:00","dateModified":"2025-07-13T20:11:27+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/02\/04\/nanoscope-announces-presentations-at-medical-meetings\/"},"wordCount":421,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/02\/04\/nanoscope-announces-presentations-at-medical-meetings\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/02\/NSCOPE_upoming_med_mtgs_feature.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/02\/04\/nanoscope-announces-presentations-at-medical-meetings\/","url":"https:\/\/nanostherapeutics.com\/2025\/02\/04\/nanoscope-announces-presentations-at-medical-meetings\/","name":"Nanoscope Therapeutics anuncia presentaciones en pr\u00f3ximos congresos m\u00e9dicos - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/02\/04\/nanoscope-announces-presentations-at-medical-meetings\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/02\/04\/nanoscope-announces-presentations-at-medical-meetings\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/02\/NSCOPE_upoming_med_mtgs_feature.jpg","datePublished":"2025-02-04T21:05:03+00:00","dateModified":"2025-07-13T20:11:27+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/02\/04\/nanoscope-announces-presentations-at-medical-meetings\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/02\/04\/nanoscope-announces-presentations-at-medical-meetings\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2025\/02\/04\/nanoscope-announces-presentations-at-medical-meetings\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/02\/NSCOPE_upoming_med_mtgs_feature.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/02\/NSCOPE_upoming_med_mtgs_feature.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/02\/04\/nanoscope-announces-presentations-at-medical-meetings\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Presentations at Upcoming Medical Meetings"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5939","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5939"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5939\/revisions"}],"predecessor-version":[{"id":9006,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5939\/revisions\/9006"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5941"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5939"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5939"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5939"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}